Biotech stocks had already been gaining ground before this week's news. In June, the iShares Nasdaq Biotechnology ETF (IBB) traded just 1.47% below its 52-week high after moving sideways since November.
Then, Moderna (MRNA) surged more than 176%, while Merck (MRK) gained over 12%, after their personalized mRNA cancer vaccine reduced melanoma recurrence in a late-stage trial. The INTerpath-001 study included 1,137 high-risk melanoma patients and delivered the first successful Phase 3 result for an individualized mRNA neoantigen therapy.
Soros Fund Management Opened a New Position in Nebius During Q2. What This Means for NBIS Stock.
Nvidia Earnings, Jackson Hole and Other Key Things to Watch this Week
Ahead of Nvidia Earnings, Here's What Barchart Data Says Comes Next for NVDA Stock
#week #Biotech #june #NASDAQ
Then, Moderna (MRNA) surged more than 176%, while Merck (MRK) gained over 12%, after their personalized mRNA cancer vaccine reduced melanoma recurrence in a late-stage trial. The INTerpath-001 study included 1,137 high-risk melanoma patients and delivered the first successful Phase 3 result for an individualized mRNA neoantigen therapy.
Soros Fund Management Opened a New Position in Nebius During Q2. What This Means for NBIS Stock.
Nvidia Earnings, Jackson Hole and Other Key Things to Watch this Week
Ahead of Nvidia Earnings, Here's What Barchart Data Says Comes Next for NVDA Stock
#week #Biotech #june #NASDAQ
2 months ago
